licensing Flashcards
what is the licensing system?
was the main novel feature of the MA 1968 (now controlled by HMR 2012) and remains at the centre of all control over medicines
what are the 3 types of license?
Marketing Authorisation (MA)
* Manufacturer’s Licence (ML)
* Wholesale Dealer’s Licence (WDL)
what are the two types of certificate?
- Clinical Trials Certificate (CTC)
- Clinical Trials Exemption Certificate (CTX)
what do licences and certificates permit?
a person or company to engage in specific,
controlled activities. Companies may therefore need more than one licence to
carry out a process
what happens if you preform an activity without a lic/ cert?
it is an offence
what is the 3 key criteria in licensing a new medicine?
safety
quality
efficacy
what is MA?
All commercially available medicinal products must have a marketing authorisation (MA) - Formerly known as ‘product licences’ (PL)
who is the MA holder?
The manufacturer of the medicinal product is usually the MA holder
what does the MA auhorise the holder to do?
- Sell, supply or export a medicinal product
- Procure its sale, supply or exportation
- Procure its manufacture
- Import it or procure its importation
how long are MA issued for?
issued for a period of time (usually 5 years or less) and may have certain restrictions attached
* After this period the MA holder must re-apply
* MHRA has power to withdraw, amend or suspend a MA
how do you obtain MA?
info has to be submitted to MHRA
If it is a new product, full information about manufacturing and testing,
including clinical trial results has to be made available to the MHRA
* A Summary of Product Characteristics (SPC) for the product must be
submitted as part of the licensing process
when is a product defined as a generic product?
- It has the same qualitative and quantitative composition in active substances as the reference medicinal product (RMP) and
- It has the same pharmaceutical form as the RMP and
- Bioequivalence with the RMP has been demonstrated
when can safety and efficacy date be used from the RMP?
after a ‘data exclusivity period’ has elapsed
* Data exclusivity period is 8 years
what is the difference between a biologic and a biosimilar?
A biologic is a medicine made from a variety of natural sources that may be human, animal or microorganism in origin, resulting in a medicine which is a biological molecule
A biosimilar is a biologic medicine that is similar to an already licensed biologic medicine in terms of safety, quality and efficacy
what must manufacturers of biosimilars submit for MA?
must submit ‘comparability data’ as part of the
licensing application
what is the early access to medicines scheme?
- Aim is to enable patients to access medicines which have not yet obtained a MA
- Only used for medicines used for life-threatening or seriously debilitating conditions and where no suitable alternative is available